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Relationship of Platelet Reactivity With Bleeding Outcomes During
Long-Term Treatment With Dual Antiplatelet Therapy for Medically
Managed Patients With Non-ST-Segment Elevation Acute Coronary
Syndromes
Jan H. Cornel, MD, PhD; E. Magnus Ohman, MD; Benjamin Neely, MS; Joseph A. Jakubowski, PhD; Deepak L. Bhatt, MD, MPH;
Harvey D. White, MB, ChB, DSc; Diego Ardissino, MD; Keith A.A. Fox, MB, ChB; Dorairaj Prabhakaran, MD, DM, MSc;
Paul W. Armstrong, MD; David Erlinge, MD, PhD; Udaya S. Tantry, PhD; Paul A. Gurbel, MD; Matthew T. Roe, MD, MHS
Background-—The relationship between “on-treatment” low platelet reactivity and longitudinal risks of major bleeding dual
antiplatelet therapy following acute coronary syndromes remains uncertain, especially for patients who do not undergo
percutaneous coronary intervention.
Methods and Results-—We analyzed 2428medically managed acute coronary syndromes patients from the Targeted Platelet Inhibition
to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial who had serial platelet reactivity
measurements (P2Y12 reaction units; PRUs) and were randomized to aspirin+prasugrel versus aspirin+clopidogrel for up to 30 months.
Contal’s method was used to determine whether a cut point for steady-state PRU values could distinguish high versus low bleeding risk
using 2-level composites: Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) severe/life-threatening or moderate
bleeding unrelated to coronary artery bypass grafting (CABG) and non-CABG Thrombolysis In Myocardial Infarction (TIMI) major or minor
bleeding. Exploratoryanalyses used3-level composites that incorporatedmildandminimalGUSTOandTIMI events.Continuousmeasures
of PRUs (per 10-unit decrease) were not independently associatedwith the 2-level GUSTO (adjusted hazard ratio [HR], 1.01; 95%CI, 0.96–
1.06) or TIMI composites (1.02; 0.98–1.07). Furthermore, no PRU cut point could signiﬁcantly distinguish bleeding risk using the 2-level
composites.However, thePRUcut point of 75differentiatedbleeding riskwith the3-level composites ofGUSTO (26.5% vs12.6%; adjusted
HR, 2.28; 95% CI, 1.77–2.94; P<0.001) and TIMI bleeding events (25.9% vs 12.2%; adjusted HR, 2.30; 95% CI, 1.78–2.97; P<0.001).
Conclusions-—Among medically managed non-ST-segment elevation acute coronary syndromes patients receiving prolonged dual
antiplatelet therapy, PRU values were not signiﬁcantly associated with the long-term risk of major bleeding events, suggesting that
low on-treatment platelet reactivity does not independently predict serious bleeding risk.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00699998. ( J Am Heart Assoc. 2016;5:
e003977 doi: 10.1161/JAHA.116.003977)
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C linical practice guidelines recommend dual antiplatelettherapy (DAPT) with aspirin+a P2Y12 inhibitor for at least
12 months for patients with acute coronary syndromes (ACS),
given the consistent beneﬁts of DAPT demonstrated in large
randomized trials.1,2 Although P2Y12 inhibitors have been
shown to reduce ischemic events, there has been a consistent
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signal of increased bleeding with DAPT treatment compared
with aspirin monotherapy, and with DAPT regimens that
include more-potent P2Y12 inhibitors (prasugrel and tica-
grelor) compared with clopidogrel.3–5 These latter observa-
tions may indicate that enhanced platelet inhibition is
associated with increased bleeding risk.
Given the consistent association of bleeding events with an
increased risk of subsequent mortality and other ischemic
outcomes, the focus of DAPT treatment is shifting toward
ﬁnding the optimal risk/beneﬁt balance for patients with ACS
to mitigate the risk of major bleeding while maintaining a
signiﬁcant reduction of ischemic events.6 In this regard, past
studies have suggested that patients undergoing percutaneous
coronary intervention (PCI) who have a robust response to a
P2Y12 inhibitor (termed low on-treatment platelet reactivity
[LPR] to ADP) have a higher risk of long-term bleeding events
following the procedure.7,8 Based on the results of these
observational studies, a therapeutic window concept for P2Y12
receptor reactivity, in which a cut-off value for high on-
treatment platelet reactivity and LPR to ADP associated with
post-PCI ischemic and bleeding event risk, has been recently
proposed.9 However, the relationship of platelet reactivity
measurements and LPR with long-term bleeding risk in patients
with ACS treated with DAPT and managed without revascular-
ization has not been prospectively evaluated.
We analyzed data from the Platelet Function Substudy (PFS)
of the Targeted Platelet Inhibition to Clarify the Optimal
Strategy to Medically Manage Acute Coronary Syndromes
(TRILOGY ACS) trial to evaluate the relationship between
measurements of platelet reactivity and the longitudinal risks of
predominantly spontaneous bleeding events among medically
managed patients with unstable angina/non-ST-segment ele-
vation myocardial infarction (UA/NSTEMI; collectively referred
to as non-ST-segment elevation acute coronary syndrome, or
NSTE ACS) who were treated with DAPT (aspirin+clopidogrel vs
aspirin+prasugrel) for up to 30 months and to determine
whether a threshold of LPR could be established that
signiﬁcantly delineated bleeding risk.
Methods
Study Population
The study design and results of the TRILOGY ACS trial have
been described.10,11 TRILOGY ACS was a double-blind, active-
controlled, randomized trial in high-risk patients with NSTE
ACS who were managed medically without planned revascu-
larization. Participants had at least 1 of 4 enrichment criteria
(age ≥60 years, diabetes mellitus, past myocardial infarction
[MI], or past coronary revascularization at least 30 days
before index ACS hospitalization). Patients with a history of
transient ischemic attack/stroke, renal failure requiring
dialysis, or concomitant oral anticoagulant treatment were
excluded. The TRILOGY ACS study was approved by regulatory
authorities in all participating countries and by participating
sites’ institutional review boards. All participants provided
written informed consent.
In the overall trial, 9326 participants at 966 sites in 52
countries were enrolled. Patients were randomly assigned to
prasugrel or clopidogrel therapy in a double-blind, double-
dummy fashion. The daily prasugrel maintenance dose was
10 mg in participants <75 years of age and 5 mg for study
participants ≥75 years of age or who weighed <60 kg. The
daily clopidogrel maintenance dose was 75 mg for all
patients. Concomitant daily treatment with aspirin was
strongly recommended, with low-dose aspirin strongly rec-
ommended. Treatment duration was up to 30 months, with a
median treatment duration of 15 months and a median
follow-up of 17 months.10 Patients who required treatment
with an oral anticoagulant (OAC) were excluded, and the study
drug was stopped if a patient required treatment with an OAC
during follow-up.
Platelet Function Substudy Protocol
A total of 25 countries participated in the TRILOGY ACS
PFS.12 All patients randomized into the main trial were
included in the PFS at participating sites in those countries.
The VerifyNow P2Y12 assay (Accriva Diagnostics, San Diego,
CA) was used to assess platelet reactivity to ADP measured in
P2Y12 reaction units (PRUs) to the randomized therapy, as
previously described.12 Sites were instructed to collect
samples only for those patients taking blinded study drug.
Platelet reactivity was assessed at baseline; at 2 hours after
ﬁrst dose of study drug; at 30 days; and at 3, 6, 12, 18, 24,
and 30 months after randomization, independent of the
occurrence of a bleeding event. Patients with at least 1 valid
PRU measurement at 30 days or later were included in the
analysis. Previous analyses from the TRILOGY ACS PFS
demonstrated little inter- and intraindividual changes in serial
PRU values over time.12
Study Endpoints
All bleeding endpoints were prespeciﬁed in the trial protocol
and were prospectively ascertained.10,11 An independent
cardiovascular adjudication committee adjudicated all sus-
pected bleeding endpoints using the TIMI (Thrombolysis In
Myocardial Infarction) bleeding classiﬁcation scale. Bleeding
endpoints were determined algorithmically from case report
form data elements using the GUSTO (Global Use Strategies
to Open Occluded Coronary Arteries) classiﬁcation scale.
Among participants who received at least 1 dose of study
drug during the “at-risk” interval of actual study drug
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treatment through 7 days after study drug discontinuation,
non–coronary artery bypass graft (CABG)-related bleeding
events were classiﬁed by the GUSTO bleeding scale as GUSTO
severe/life-threatening, moderate, or mild bleeding, and by
the TIMI bleeding scale as major, minor, or minimal, as
previously deﬁned.11 The primary analyses used the 2-level
composite GUSTO and TIMI bleeding endpoints (GUSTO
severe/life-threatening or moderate bleeding; TIMI major or
minor bleeding), given that we chose to focus upon conse-
quential and clinically meaningful bleeding events that
typically result in hospitalization. Further exploratory analyses
extended to the 3-level composite bleeding endpoints for
each classiﬁcation scale (GUSTO severe/life-threatening,
moderate, or mild bleeding; TIMI major, minor, or minimal
bleeding), given the potential effects of mild/minimal bleeding
events on study drug compliance. All bleeding analyses
included only the 9240 patients who received at least 1 dose
of the study drug.
Statistical Analysis
For this analysis, the “steady-state” PRU values were deﬁned as
those occurring at 5 days postrandomization, given that the
ﬁrst 2 PRU measurements obtained (at baseline and 2 hours
following ﬁrst study drug administration) did not reﬂect steady-
state PRU values that would only be expected to occur after at
least 5 days of treatment with maintenance doses of prasugrel
or clopidogrel (there was no “reloading” of clopidogrel and
prasugrel at the time of randomization for the 95% of patients
who had been receiving clopidogrel before randomization).10 To
account for events that occurred between 5 and 30 days
postrandomization, we assumed that the 30-day PRU value (the
next value assessed after the 2-hour value per the study
protocol) represented “steady-state treatment” at 5 days
(when it was impractical to require patients to have an
additional study visit solely for PRU measurement). Missing
PRU values with a valid value after day 30 were used as the
PRU value at 5 days (backward imputation). Forward imputa-
tion was used for patients randomized to clopidogrel who were
already taking clopidogrel at home and had missing PRU values
at 30 days or later (patient exclusions and imputation details
are contained in Figure S1).12
Baseline characteristics were compared by tertiles of
steady-state PRU values to demonstrate how patient clinical
characteristics differed by 3 categories of PRU response to
the randomized study drug (clopidogrel vs prasugrel). Contin-
uous variables are presented as medians and interquartile
ranges. Categorical variables are presented as counts and
percentages. Differences in baseline characteristics were
tested among tertiles of steady-state PRU values. Continuous
variables were compared using ANOVA when the assumption
of normality was satisﬁed; otherwise, the Kruskal–Wallis test
was used. Categorical variables were compared using the chi-
square test when cell frequencies were sufﬁcient; otherwise,
an exact test was used. Kaplan–Meier plots for the bleeding
endpoints by PRU tertiles were analyzed for the 2-level
composite bleeding endpoints.
To determine whether a PRU cut point existed that
distinguished between high- and low-risk bleeding patients,
we used the method of Contal and O’Quigley.13 This method
considers all possible observed values of steady-state PRU
values and derives a standardized score statistic that can be
used to test the null hypothesis that all observed values have
equally likely risks of bleeding using the 2-level composites of
GUSTO severe/life-threatening or moderate bleeding and TIMI
major or minor bleeding. This test was used to determine
whether the cut point that maximizes the score value is
statistically different from other cut points with similar score
values. However, given results from a past study that only
demonstrated associations with clopidogrel metabolizer geno-
mic variants and composite bleeding outcomes that incorpo-
rated mild bleeding events, we also separately performed
analyses for PRU cut points that incorporated the 3-level
composite bleeding endpoints for each classiﬁcation scale
(GUSTO severe/life-threatening, moderate, or mild bleeding;
and TIMI major, minor, or minimal bleeding) to comprehensively
assess the relationship between PRU values and bleeding
risk.14 As a result, 4 separate PRU cut points were determined.
To explore the unadjusted relationship between PRU
values and bleeding outcomes, we grouped individuals
according to the PRU value that maximized the score
statistic regardless of whether it was a signiﬁcant cut point.
We then used these groups to create Kaplan–Meier plots of
the cumulative distribution function and used the log-rank
test to determine whether the survival functions (for
bleeding endpoints) differed signiﬁcantly between the
groups. This testing procedure was analyzed completely
separately for each of the 2- and 3-level composite GUSTO
and TIMI bleeding composite outcomes (as previously
described) to determine whether each of the 4 derived
PRU cut points could reliably distinguish high versus low
bleeding risk using the different composite outcomes from
both bleeding classiﬁcation scales.
To account for potential imbalances in baseline character-
istics, we derived Cox proportional hazards models to assess
the adjusted association between steady-state PRU values
and time to ﬁrst bleed using the GUSTO and TIMI bleeding
composite endpoints, as previously described. Based upon
previous analyses, we chose to use the following variables for
adjustment: weight, age, clopidogrel stratum at time of
randomization, aspirin dose category, time from randomization
to treatment start, sex, disease classiﬁcation, Killip class,
previous peripheral arterial disease, previous peptic ulcer
disease, systolic blood pressure, baseline hemoglobin, baseline
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creatinine, baseline (prerandomization) PRU values, and con-
comitant beta-blocker use.15–17 Additionally, we included a
variable unique to TRILOGY ACS (use of angiography before
randomization) given a previous analysis that demonstrated
higher rates of bleeding for patients who underwent angiog-
raphy before randomization.18 To explore the relationship
between steady-state PRU and time to ﬁrst bleeding event, we
constructed a series of models to evaluate the relationship
between steady-state high versus low PRU values using the
cut points we derived and PRU values (in a continuous
fashion) with the 2- and 3-level GUSTO and TIMI composite
bleeding endpoints.13 We also analyzed the adjusted risks of
bleeding in a restricted population of patients aged <75 years
who were included in the primary efﬁcacy analysis population
of the overall TRILOGY ACS trial given that an exploratory
treatment regimen (prasugrel 5 mg/day vs clopidogrel
75 mg/day) was studied in the elderly population (age
≥75 years).10,11 Also, we performed a sensitivity analysis to
evaluate the interactions between day 5 PRU values and
randomized treatment with respect to bleeding outcomes.
All statistical tests were performed at a signiﬁcance level of
0.05. All analyses were performed using SAS (version 9.3; SAS
Institute Inc., Cary, NC) and R (version 2.14.1; R Foundation for
Statistical Computing, Vienna, Austria) software by statisticians
at the Duke Clinical Research Institute (Durham, NC), with an
independent copy of the database. Dr Roe, the principal
investigator for the TRILOGY ACS trial, had full access to all the
data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analyses.
Results
Platelet Function Substudy Participation
Among 9326 patients enrolled in TRILOGY ACS, 2690 (28%)
were initially enrolled in the PFS. After database lock, it was
determined that 13 of these patients were inaccurately listed
as included in the PFS at randomization and 126 did not have
a valid PRU measurement recorded, leaving a total of 2564
patients. Among the patients who received at least 1 dose of
study drug, 2428 (26% of the total population) had a valid PRU
measurement recorded at 30 days (for imputation of day 5
PRU results), and these patients were included in our analysis
(Figure S1).
As previously published, the baseline clinical characteris-
tics and efﬁcacy (ischemic) outcomes were similar for
patients who did versus did not participate in the PFS, and
bleeding composite outcomes were also similar.12 Frequen-
cies of GUSTO severe/life-threatening or moderate bleeding
events and TIMI major or minor bleeding events were lower
for patients who did versus did not participate in the PFS
(Table S1).
Baseline Characteristics
Among the 2428 participants included in this analysis,
baseline characteristics stratiﬁed by tertiles of baseline PRU
values are shown in Table 1. Compared with participants in
the middle and highest tertiles, participants in the lowest PRU
tertile (PRU <105) were younger; more likely to be male; less
likely to have diabetes mellitus; had higher body weight,
higher baseline hemoglobin levels, and higher baseline
creatinine clearance values; had a lower median Global
Registry of Acute Coronary Events (GRACE) risk score; more
commonly received the prasugrel 10-mg dose; and had the
lowest median baseline PRU values assessed at the time of
randomization before the ﬁrst dose of study drug was
administered (when 95% of the participants were being
treated for the index ACS event with prerandomization
clopidogrel). More elderly patients (≥75 years) and those
with low body weight (<60 kg) were present in the highest
PRU tertile (PRU >211), likely attributed to the use of a lower
dose of prasugrel (5 mg) for these key subgroups. Baseline
characteristics by the PRU cut point of <75 are detailed in
Table S2.
Unadjusted Bleeding Outcomes
Using the 2-level composite bleeding endpoints for the
primary analyses, 28 GUSTO severe/life-threatening or
moderate bleeding events and 39 TIMI major or minor
bleeding events not related to CABG occurred from
randomization through the end of study follow-up. Starting
at the landmark of 5 days postrandomization (the starting
point for this analysis that corresponds with the steady-
state day 5 PRU values), there were 27 GUSTO severe/life-
threatening or moderate bleeding events and 37 TIMI major
or minor bleeding events not related to CABG that were
included in these analyses. Gastrointestinal bleeding was
the most common location for both GUSTO and TIMI
bleeding events (Table 2). Bleeding event curves through
30 months by PRU tertiles overlapped during the ﬁrst
12 months. The highest rates of bleeding through
30 months were observed for the middle PRU tertile (PRU
106–211) for both GUSTO and TIMI 2-level composite
bleeding events (Figure 1A and 1B).
Using the 3-level composite bleeding endpoints, there
were 297 GUSTO severe/life-threatening, moderate, or mild
bleeding events and 290 TIMI major, minor, or minimal
bleeding events, with bleeding locations shown in Table S3.
PRU Cut Points to Deﬁne Bleeding Risk
Using the method of Contal and O’Quigley, the best PRU cut
points identiﬁed for GUSTO severe/life-threatening or
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Table 1. Baseline Characteristics Stratiﬁed by Tertiles of P2Y12 Reaction Unit (PRU) Values
Variable
Day 5 PRU Tertiles
P Value
PRU ≤105
(n=817)
PRU 106 to 211
(n=803)
PRU >211
(n=808)
Demographics
Age, y* 63 (57, 70) 66 (59, 73) 67 (60, 75) <0.001
≥75 y (%) 84/817 (10.3) 167/803 (20.8) 217/808 (26.9) <0.001
Female sex (%) 277/817 (33.9) 293/803 (36.5) 376/808 (46.5) <0.001
Weight, kg* 76.0 (65.8, 87.5) 75.0 (64.2, 87.0) 74.0 (62.3, 85.0) 0.002
<60 kg (%) 86/817 (10.5) 139/803 (17.3) 149/808 (18.4) <0.001
Disease classification (%)
NSTEMI 555/817 (67.9) 524/803 (65.3) 545/808 (67.5) 0.476
History (%)
Diabetes mellitus 270/816 (33.1) 291/801 (36.3) 341/808 (42.2) <0.001
Past MI 375/810 (46.3) 343/802 (42.8) 340/801 (42.4) 0.224
Past PCI 225/815 (27.6) 220/801 (27.5) 199/805 (24.7) 0.335
Past CABG 100/817 (12.2) 111/803 (13.8) 132/806 (16.4) 0.054
Past PAD 42/804 (5.2) 37/790 (4.7) 50/790 (6.3) 0.337
Past atrial fibrillation 51/802 (6.4) 76/791 (9.6) 78/791 (9.9) 0.021
Past heart failure 148/808 (18.3) 168/795 (21.1) 166/801 (20.7) 0.313
Past peptic ulcer disease 50/809 (6.2) 51/800 (6.4) 39/802 (4.9) 0.371
Baseline risk assessment
Systolic BP, mm Hg* 127 (115, 138) 127 (116, 139) 130 (120, 140) 0.14
Killip class II to IV (%) 80/817 (9.8) 83/803 (10.3) 120/807 (14.9) 0.002
GRACE risk score* 115 (42, 201) 122 (54, 189) 126 (59, 205) <0.001
Creatinine, mg/dL* 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 0.548
CrCl, mL/min* 80.5 (61.3, 104.2) 73.9 (56.2, 97.8) 68.9 (51.1, 91.8) <0.001
Hemoglobin, g/dL* 14.0 (13.1, 15.1) 13.8 (12.8, 14.9) 13.2 (12.2, 14.1) <0.001
Prerandomization procedures (%)
Angiography performed 334/817 (40.9) 313/803 (39.0) 295/808 (36.5) 0.193
Medications at randomization (%)
Aspirin, daily dose, mg
<100 325/817 (39.8) 343/803 (42.7) 300/808 (37.1) 0.073
100 to 250 361/817 (44.2) 353/803 (44.0) 394/808 (48.8) 0.091
>250 59/817 (7.2) 59/803 (7.3) 56/808 (6.9) 0.946
Beta-blocker 645/817 (78.9) 620/803 (77.2) 606/808 (75.0) 0.166
ACE-I/ARB 571/817 (69.9) 582/803 (72.5) 603/808 (74.6) 0.102
Statin 682/817 (83.5) 657/803 (81.8) 662/808 (81.9) 0.618
Proton pump inhibitor 164/817 (20.1) 210/803 (26.2) 193/808 (23.9) 0.014
Randomization-specific information
Clopidogrel stratum (%) 0.08
No prerandomization clopidogrel 35/817 (4.3) 38/803 (4.7) 40/808 (5.0)
Clopidogrel started in-hospital; continued to randomization 578/817 (70.7) 516/803 (64.3) 537/808 (66.5)
Home clopidogrel continued to randomization 204/817 (25.0) 249/803 (31.0) 231/808 (28.6)
Continued
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moderate bleeding events (PRU <106) and TIMI major or
minor bleeding events (PRU <46) for the primary analyses did
not signiﬁcantly distinguish longitudinal bleeding risks using
these 2-level bleeding composite endpoints (Figure 2A and
2B). For the exploratory analyses, the separately determined
PRU cut points that maximized the score statistic were <75
both for the 3-level composite of GUSTO severe/life-
threatening, moderate, or mild bleeding events (unadjusted
bleeding rates=26.5% for PRU values <75 vs 12.6% for PRU
values ≥75) and for the 3-level composite of TIMI major,
minor, or minimal bleeding events (unadjusted bleeding
rates=25.9% vs 12.2%, respectively). Bleeding event curves
distinguished by this cut point of <75 PRU (using the 3-level
composite bleeding endpoints) separated early and continued
to separate during the trial follow-up period (Figure 2C and
2D).
Adjusted Bleeding Outcomes
For the primary analyses, no signiﬁcant association was found
between continuous measures of PRU (per 10-unit decrease)
with the adjusted risk of the 2-level composites of GUSTO
severe/life-threatening or moderate bleeding or with TIMI
major or minor bleeding (Table 3). For the exploratory
analyses, using the 3-level GUSTO and TIMI composite
bleeding endpoints that incorporated GUSTO mild and TIMI
minimal bleeds, respectively, there was a signiﬁcant increase
in bleeding risk with continuous measures of PRU (per 10-unit
decrease).
When the derived LPR cut points of PRU <46 for TIMI
bleeding and PRU <106 for GUSTO bleeding were analyzed
for the primary analyses, there was no signiﬁcant associ-
ation with the adjusted risk of the 2-level composites of
GUSTO severe/life-threatening or moderate bleeding for
PRU values below versus above the LPR cut point, and
there was a marginally signiﬁcant association with the
adjusted risk of TIMI major or minor bleeding. For the
exploratory analyses, there was an association with PRU
values below versus above the LPR cut point of 75 for both
the adjusted risks of the 3-level composites of GUSTO
severe/life-threatening, moderate, or mild bleeding and for
the TIMI major, minor, or minimal bleeding. Similar adjusted
results were observed in the sensitivity analysis of the
restricted population of patients aged <75 years (Table S4).
Additional modeling showed no signiﬁcant interactions
between day 5 PRU values, randomized treatment, and
bleeding outcomes.
Discussion
These hypothesis-generating ﬁndings demonstrate no clear
relationship between LPR and the longitudinal risks of serious
bleeding events (using both the GUSTO and TIMI bleeding
classiﬁcation scales) among patients with NSTE ACS who
were managed without revascularization and treated with
Table 1. Continued
Variable
Day 5 PRU Tertiles
P Value
PRU ≤105
(n=817)
PRU 106 to 211
(n=803)
PRU >211
(n=808)
Randomized to prasugrel (%) 643/817 (78.7) 359/803 (44.7) 200/808 (24.8) <0.001
Prasugrel 5-mg dose† 98/643 (15.2) 156/359 (43.5) 102/200 (51.0) <0.001
Baseline, pre-randomization PRU* 181 (120, 250) 215 (163, 274) 273 (219, 315) <0.001
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CABG, coronary artery bypass grafting; CrCl, creatinine clearance; GRACE,
Global Registry of Acute Coronary Events; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary
intervention; PRU, P2Y12 reaction unit.
*Median (25th, 75th percentiles).
†Percentage of the overall patient group from each PRU tertile who received the prasugrel 5 mg/day maintenance dose.
Table 2. Distribution of Bleeding Locations for the Primary
Analyses (2-Level Bleeding)
Location
GUSTO Severe/Life-Threatening
or Moderate Bleeding
TIMI Major or
Minor Bleeding
Epistaxis — 1
Gastrointestinal 11 22
Hematuria — 1
No site identified 4 —
Other 4 4
Subdural hematoma 2 2
Surgical incision site 2 2
Urethral 1 1
Vaginal 1 2
Vascular access site 1 1
Missing 1 1
Total 27 37
GUSTO indicates Global Use of Strategies to Open Occluded Coronary Arteries; TIMI,
Thrombolysis In Myocardial Infarction.
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prolonged DAPT for up to 30 months. Only when mild/
minimal events were incorporated into composite bleeding
endpoints was an association with low PRU values and
bleeding risk demonstrated. Frequency of TIMI major or minor
bleeding over 30 months was low (1.5%), however, and
bleeding was primarily gastrointestinal in origin.
Figure 1. Cumulative Kaplan–Meier (KM) estimates of Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO) severe/life-threatening (LT) or moderate (A) and Thrombolysis In Myocardial Infarction (TIMI)
major or minor (B) bleeding events by P2Y12 reaction unit (PRU) tertiles of distribution.
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This is the ﬁrst large study that evaluated the 5-mg
prasugrel dose used to mitigate bleeding risk and the
relationship of PRU values with bleeding risk in patient
populations that are vulnerable and eligible for this dose (ie,
those with low body weight and the elderly). However, our
ﬁndings highlight how clinical characteristics associated with
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Figure 2. Cumulative Kaplan–Meier (KM) estimates of Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO) severe/life-threatening (LT), or moderate bleeding (A); Thrombolysis In Myocardial Infarction
(TIMI) major or minor bleeding (B); GUSTO severe/LT, moderate, or mild bleeding (C); and TIMI major, minor, or
minimal bleeding (D) events by the derived low platelet reactivity cut point in P2Y12 reaction units (PRUs).
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bleeding risk strongly inﬂuence platelet response to P2Y12
inhibitors and thus may confound any potential relationship
between PRU values and risks of serious bleeding events. In
the current study, patients in the lowest PRU tertile (PRU
≤105) were younger, had higher body weight, and had higher
baseline creatinine clearance and hemoglobin values—all
factors that are known to be associated with a lower risk of
short- and intermediate-term bleeding among patients with
ACS.19–23 Whereas patients in the lowest PRU tertile were
more likely to be randomized to prasugrel and receive the
prasugrel 10-mg maintenance dose (as expected from our
previous evaluation of the PFS data according to randomized
treatment assignment), the unadjusted risks of GUSTO
severe/life-threatening or moderate and TIMI major or minor
bleeding were highest among patients in the middle PRU
tertile (PRU 106–211). Additionally, we have separately
shown that elderly patients (≥75 years) from the TRILOGY
ACS study population had a 2- to 3-fold increased risk of both
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Figure 2. continued.
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GUSTO and TIMI bleeding (using 2-level bleeding composite
endpoints) when treated with either clopidogrel 75 mg/day
or prasugrel 5 mg/day, as compared to younger patients.24
The underlying factors associated with increased bleeding
risks for elderly patients are likely multifactorial (lower body
weight, lower baseline creatinine clearance, and lower
hemoglobin values compared to younger patients) and
inter-related, but we observed similar ﬁndings in our
adjusted analysis of the relationship of PRU values with
bleeding risks when elderly patients were excluded. We
previously observed that elderly patients had a less-robust
PRU response to clopidogrel 75 mg daily compared to
younger patients, so older age may be a much stronger
contributor to bleeding risk irrespective of on-treatment PRU
response to a P2Y12 inhibitor.
12 Finally, our study is the ﬁrst
large study that included both a third-generation P2Y12
inhibitor (prasugrel) and clopidogrel when assessing the
association of bleeding risk with PRU values. Further
investigation is therefore needed to ascertain how interac-
tions between clinical characteristics, the dose/type of
P2Y12 inhibitor chosen for an individual patient, and on-
treatment PRU values inﬂuence serious bleeding rates.
In contrast to the medically managed population studied in
TRILOGY ACS, observational studies in patients treated with
PCI have suggested that LPR during DAPT treatment may be
associated with major bleeding risk.7–9,25,26 A prospective,
randomized trial that leveraged bedside PRU monitoring to
inform antiplatelet treatment decisions did not conﬁrm this
relationship, but ﬁndings from the ADAPT-DES prospective
registry demonstrated an inverse relationship between high
platelet reactivity (PRU >208) and clinically relevant bleeding
in patients undergoing PCI.23,27,28 After successful PCI, lower
platelet reactivity on clopidogrel was an independent predic-
tor of postdischarge bleeding, and these bleedings had a
strong relationship with mortality at the 2-year follow-up
point.23 Another recent study in a cohort of patients who
underwent elective PCI suggested that LPR provided incre-
mental predictive value for bleeding events through 30 days
compared with a bleeding risk score.29 Although the inﬂuence
of platelet reactivity on bleeding risk may differ for patients
who undergo PCI versus ACS patients who are managed
without revascularization, the primary 2-level composite
bleeding events in TRILOGY ACS occurred infrequently and
were primarily spontaneous and unrelated to cardiovascular
procedures. The present analysis from TRILOGY ACS thus
provides novel evidence for the relationship of platelet
reactivity measurements with bleeding risk for ACS patients
treated with DAPT who did not undergo PCI.
Limitations
A number of limitations to our analysis should be noted. First,
PRU values were missing across all time periods, and multiple
imputation techniques were used to account for missing
values. The back-imputation technique used to estimate day 5
PRU values requires assumptions about the stability of drug
effects and steady state at 5 days postbaseline that may not
be accurate. Second, the number of serious bleeding events
was small, so this study was underpowered to determine
whether there was a signiﬁcant difference in bleeding risk
using the 2-level composite GUSTO and TIMI bleeding
outcomes. However, this is the largest platelet function
substudy that has been embedded within a randomized
clinical trial comparing post-ACS DAPT regimens beyond
clopidogrel, so it is unlikely that a larger study will be
conducted in the future to capture more-serious bleeding
events. Third, the frequencies of GUSTO severe/life-threaten-
ing or moderate bleeding events and TIMI major or minor
bleeding events were lower for patients who did versus did
not participate in the PFS. These ﬁndings could be attributed
to regional differences in the reporting and/or querying of
suspected bleeding events that were further confounded by
Table 3. Adjusted Associations of GUSTO and TIMI
Composite Bleeding Deﬁnitions With Continuous PRU
Distributions and the Derived Cut Points for Low Versus High
Platelet Reactivity in All Patients
Adjusted HR
(95% CI) P Value
GUSTO severe/life-threatening or moderate non-CABG bleeding
Continuous day 5 PRU (per 10-unit
decrease)
1.01 (0.96–1.06) 0.82
Dichotomous (<106) day 5 PRU (LPR
vs HPR)*
0.68 (0.25–1.87) 0.46
GUSTO severe/life-threatening, moderate, or mild non-CABG bleeding
Continuous day 5 PRU (per 10-unit
decrease)
1.04 (1.02–1.05) <0.001
Dichotomous (<75) day 5 PRU (LPR
vs HPR)*
2.30 (1.72–3.07) <0.001
TIMI major or minor non-CABG bleeding
Continuous day 5 PRU (per 10-unit
decrease)
1.02 (0.98–1.07) 0.37
Dichotomous (<46) day 5 PRU (LPR
vs HPR)*
2.35 (1.00–5.52) 0.05
TIMI major, minor, or minimal non-CABG bleeding
Continuous day 5 PRU (per 10-unit
decrease)
1.04 (1.02–1.06) <0.001
Dichotomous (<75) day 5 PRU (LPR
vs HPR)*
2.34 (1.74–3.14) <0.001
CABG indicates coronary artery bypass graft; GUSTO, Global Use of Strategies to Open
Occluded Coronary Arteries; HPR, high platelet reactivity; HR, hazard ratio; LPR, low
platelet reactivity; PRU, P2Y12 reaction unit; TIMI, Thrombolysis In Myocardial Infarction.
*The 4 derived cut points to determine bleeding risk were separately determined for
each of the 2- and 3-level TIMI and GUSTO composite bleeding outcomes.
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the choice of countries that participated in the PFS, but we
were not able to investigate these potential assumptions.
Finally, we did not analyze how clopidogrel metabolizer
genomic variants inﬂuenced the relationship of bleeding risk
with DAPT treatment in this analysis because we chose to
focus solely upon the relationship of platelet reactivity
measurements (regardless of genomic status and type/dose
of P2Y12 inhibitor used).
14
Conclusions
Among NSTE ACS patients managed without revascularization
and receiving prolonged DAPT treatment, PRU values were not
signiﬁcantly associated with long-term serious bleeding risk.
These hypothesis-generating results suggest that LPR does
not independently predict the risk of serious bleeding during
the period of DAPT treatment post-ACS.
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Figure S1. Consort diagram demonstrating patient flow and PRU imputation approaches 
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Table S1. Bleeding event rates by participation in the PFS* 
 
Included in PFS 
(N=2428) 
Not Included in PFS 
(N=6812) 
GUSTO severe/life-threatening or 
moderate bleeding (%) 
1.83% 3.63% 
TIMI major or minor bleeding (%) 2.24% 3.81% 
*Kaplan-Meier estimates of bleeding rates through 30 months  
PFS, Platelet Function Sub-Study 
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Table S2. Baseline characteristics stratified by PRU values 
 
PRU <75  
(N=601) 
PRU ≥75  
(N=1827) 
P-
value 
Demographics    
Age, yrs  62.0 (56.0, 
69.0) 
66.0 (60.0, 
74.0) 
<0.00
1 
Female sex 212/601 
(35.3) 
734/1827 
(40.2) 
0.033 
White race 388/601 
(64.6) 
1120/1827 
(61.3) 
0.153 
Weight, kg 76.0 (66.7, 
87.5) 
75.0 (63.0, 
86.1) 
0.004 
NSTEMI 403/601 
(67.1) 
1221/1827 
(66.8) 
0.919 
Killip class II-IV 52/601 (8.7) 231/1826 
(12.7) 
0.008 
Time from FMC to treatment start, hrs 99.8 (54.9, 
157.8) 
108.9 (63.0, 
160.9) 
0.211 
CV risk factors    
Family history of CAD 179/536 
(33.4) 
503/1640 
(30.7) 
0.238 
Hypertension 480/598 
(80.3) 
1508/1823 
(82.7) 
0.174 
Hyperlipidemia 318/541 
(58.8) 
1011/1699 
(59.5) 
0.765 
Diabetes mellitus 190/600 
(31.7) 
712/1825 
(39.0) 
0.001 
Current/recent smoking 118/594 
(19.9) 
322/1808 
(17.8) 
0.261 
Prior peptic ulcer disease 38/596 (6.4) 102/1815 0.494 
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PRU <75  
(N=601) 
PRU ≥75  
(N=1827) 
P-
value 
(5.6) 
Angiography performed 252/601 
(41.9) 
690/1827 
(37.8) 
0.069 
CV disease history    
Prior myocardial infarction 282/595 
(47.4) 
776/1818 
(42.7) 
0.044 
Prior PCI 170/599 
(28.4) 
474/1822 
(26.0) 
0.256 
Prior CABG 72/601 (12.0) 271/1825 
(14.8) 
0.080 
Prior PAD 28/590 (4.7) 101/1794 
(5.6) 
0.410 
Prior atrial fibrillation 33/589 (5.6) 172/1795 
(9.6) 
0.003 
Prior chronic heart failure 110/593 
(18.5) 
372/1811 
(20.5) 
0.293 
Baseline labs and measurments    
GRACE risk score 114.0 (42.0, 
201.0) 
123.0 (54.0, 
205.0) 
<0.00
1 
Creatinine 1.0 (0.8, 1.1) 1.0 (0.8, 1.2) 0.094 
CrCL, mL/min 82.3 (62.5, 
105.6) 
71.8 (54.0, 
94.7) 
<0.00
1 
Systolic BP, mmHg 127.0 (115.0, 
138.0) 
129.0 (118.0, 
140.0) 
0.334 
Heart rate, bpm 68.0 (61.0, 
75.0) 
70.0 (62.0, 
76.0) 
0.068 
Hemoglobin 14.0 (13.0, 
15.1) 
13.5 (12.5, 
14.6) 
<0.00
1 
Concomitant medications at    
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PRU <75  
(N=601) 
PRU ≥75  
(N=1827) 
P-
value 
randomization 
Daily dose <100 mg 233/601 
(38.8) 
735/1827 
(40.2) 
0.526 
Daily dose 100-250 mg 266/601 
(44.3) 
842/1827 
(46.1) 
0.435 
Daily dose >250 mg 43/601 (7.2) 131/1827 
(7.2) 
0.990 
Beta-blocker 476/601 
(79.2) 
1395/1827 
(76.4) 
0.150 
ACE-I/ARB 419/601 
(69.7) 
1337/1827 
(73.2) 
0.100 
Statin 502/601 
(83.5) 
1499/1827 
(82.0) 
0.408 
Proton pump inhibitor 121/601 
(20.1) 
446/1827 
(24.4) 
0.032 
Randomization specific information    
Clopidogrel strata   0.014 
1 24/601 (4.0) 89/1827 (4.9)  
2 433/601 
(72.0) 
1198/1827 
(65.6) 
 
3 144/601 
(24.0) 
540/1827 
(29.6) 
 
Randomized treatment 503/601 
(83.7) 
699/1827 
(38.3) 
<0.00
1 
Duration of clopidogrel use before 
treatment start, hrs 
108.3 (62.8, 
149.3) 
107.9 (65.0, 
156.6) 
0.794 
Age ≥75 yrs 41/601 (6.8) 427/1827 
(23.4) 
<0.00
1 
Weight <60 kg 50/601 (8.3) 324/1827 <0.00
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PRU <75  
(N=601) 
PRU ≥75  
(N=1827) 
P-
value 
(17.7) 1 
Prasugrel maintenance 5 mg 54/503 (10.7) 302/699 
(43.2) 
<0.00
1 
Baseline PRU values 179.0 (115.0, 
249.0) 
238.0 (179.0, 
295.0) 
<0.00
1 
Data are presented as medians (25th, 75th percentiles) or n/N (%). 
ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BP, blood pressure; 
CAD, coronary artery disease; CABG, coronary artery bypass graft; CrCl, creatinine clearance; CV, 
cardiovascular; FMC, first medical contact; GRACE, Global Registry of Acute Coronary Events; PAD, 
peripheral artery disease; PCI, percutaneous coronary intervention; PFS, Platelet Function Substudy; PRU, 
P2Y12 reaction unit; NSTEMI, non-ST-segment elevation myocardial infarction. 
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Table S3. Distribution of bleeding locations for the exploratory analyses (3-level bleeding) 
 
Location 
GUSTO severe/life-
threatening or moderate or 
mild bleeding 
TIMI major or minor or 
minimal bleeding 
Breast 1 1 
Epistaxis 47 50 
Gastrointestinal 63 59 
Hematuria 10 10 
Hemoptysis 6 6 
Intraocular 3 3 
No site identified 9 . 
Other 132 136 
Subdural hematoma 1 1 
Surgical incision site 8 7 
Urethral 2 2 
Vaginal 5 5 
Vascular access site 9 9 
Missing 1 1 
Total 297 290 
GUSTO indicates Global Use of Strategies to Open Occluded Coronary Arteries; TIMI, Thrombolysis In 
Myocardial Infarction. 
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Table S4. Adjusted associations of GUSTO and TIMI composite bleeding definitions with 
continuous PRU Distributions and the derived cut-points for low vs. high platelet reactivity 
restricted to patients aged <75 years 
  
 
Adjusted HR  
(95% CI) 
P 
GUSTO severe/life-threatening or moderate non-CABG 
bleeding 
  
Continuous day 5 PRU (per 10-unit decrease) 1.01 (0.95–1.06) 0.85 
Dichotomous (<106) day 5 PRU (LPR vs. HPR) 0.61 (0.20–1.84) 0.38 
GUSTO severe/life-threatening, moderate, or mild non-CABG 
bleeding 
  
Continuous day 5 PRU (per 10-unit decrease) 1.04 (1.03–1.06) <0.001 
Dichotomous (<75) day 5 PRU (LPR vs. HPR) 2.19 (1.61–2.98) <0.001 
TIMI major or minor non-CABG bleeding   
Continuous day 5 PRU (per 10-unit decrease) 1.02 (0.98–1.07) 0.35 
Dichotomous (<46) day 5 PRU (LPR vs. HPR) 1.99 (0.81–4.90) 0.13 
TIMI major, minor, or minimal non-CABG bleeding   
Continuous day 5 PRU (per 10-unit decrease) 1.04 (1.03–1.06) <0.001 
Dichotomous (<75) day 5 PRU (LPR vs. HPR) 2.21 (1.62–3.02) <0.001 
CABG, coronary artery bypass graft; CI, confidence interval; GUSTO, Global Use of Strategies to Open 
Occluded Coronary Arteries; HPR, high platelet reactivity; HR, hazard ratio; LPR, low platelet reactivity; 
PRU, P2Y12 reaction unit; TIMI, Thrombolysis In Myocardial Infarction. 
 
D
ow
nloaded from
 http://ahajournals.org by on January 23, 2019
